Acute Treatment Optimization Influences Disability and Quality of Life in Migraine: Results of the ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) Study (4154)

Objective: Assess the influence of acute treatment optimization and migraine related disability and health related quality of life (HRQoL) across monthly Migraine Headache Day (MHD) categories from the OVERCOME study. Background: Acute treatments for migraine attacks are considered optimized when they resolve pain and restore function. Optimized acute treatment for migraine should be associated with less disability and better HRQoL in people with migraine. Design/Methods: OVERCOME is a web-based survey conducted in a representative US sample. The current sample, collected in Spring 2019, included 20,041 people meeting ICHD-3 criteria for migraine who completed measures of acute treatment optimization (Migraine Treatment Optimization Questionnaire [mTOQ]), disability (Migraine Disability Assessment Scale [MIDAS], and HRQoL (Migraine-Specific Quality of Life Questionnaire, Role Function – Restrictive subscale [MSQ-RFR]). This analysis examined the relationship between mTOQ, MIDAS, and MSQ-RFR across MHDs per month categories (0–3, 4–7, 8–14, ≥15 MHDs). One-way ANOVA or Chi-square test, stratified by MHD category, evaluated differences between mTOQ groups (p Results: For the whole cohort of 20,041 respondents, mean(SD) age was 42.5(14.9) years, 74.9% were female, and 72.1% were non-Hispanic white. Among the 3,938 respondents with 4–7 MHDs per month, 60.1% of those with very poor treatment optimization had severe MIDAS disability as opposed to only 19.5% of those with maximum treatment optimization (p Conclusions: When acute migraine treatment is optimized, people with migraine report lower levels of disability and better health related quality of life. Disclosure: Dr. Buse has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Avanir, Amgen, Biohaven, Eli Lilly and Company, and Promius and for work on the editorial board of Current Pain and Headache Reports.. Dr. Buse has received personal compensation in an editorial capacity for Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Avanir, Amgen, Biohaven, Eli Lilly and Company, and Promius and for work on the editorial board of Current Pain and Headache Reports.. Dr. Buse has received research support from Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Avanir, Amgen, Biohaven, Eli Lilly and Company, and Promius and for work on the editorial board of Current Pain and Headache Reports.. Dr. Kovacik has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Nicholson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Nicholson has received compensation for serving on the Board of Directors of Eli Lilly and Company. Dr. Nicholson holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Nicholson was involved as an investigator. Dr. Nicholson holds stock and/or stock options in Eli Lilly and Company. Dr. Nicholson has received research support from Eli Lilly and Company. Dr. Doty has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Doty holds stock and/or stock options in Eli Lilly. Dr. Araujo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Ashina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Eli Lilly, Promius, Satsuma, Supernus, Theranica, Novartis, and Amgen.Dr. Reed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with OVERCOME study advisory board. Dr. Reed has received research support from Michael L. Reed, PhD, is Managing Director of Vedanta Research, which has received research funding from Allergan, Amgen, Promius/Dr. Reddy9s Laboratories, Eli Lilly and Company, GlaxoSmithKline, Merck \u0026 Co., Inc., Novartis the National Headache Foundatio.Dr. Shapiro has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company for consulting on research studies. Dr. Kim has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Lipton has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Lipton holds stock and/or stock options in Biohaven which sponsored research in which Dr. Lipton was involved as an investigator. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Lipton has received research support from Migraine Research Foundation the National Headache Foundation and Amgen.